INO - Inovio Pharmaceuticals Inc. (INO) Q1 2024 Earnings Call Transcript
2024-05-13 19:47:09 ET
Inovio Pharmaceuticals, Inc. (INO)
Q1 2024 Earnings Conference Call
May 13, 2024, 04:30 PM ET
Company Participants
Thomas Hong - Manager of Investor Relations
Jacqueline Shea - President and Chief Executive Officer
Michael Sumner - Chief Medical Officer
Mark Twyman - Chief Commercial Officer
Peter Kies - Chief Financial Officer
Conference Call Participants
Hartaj Singh - Oppenheimer
Roy Buchanan - JMP
Anish Nikhanj - RBC Capital Markets
Roger Song - Jefferies
Yi Chen - H.C. Wainwright
Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the INOVIO First Quarter 2024 Financial Results Conference Call. At this time all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Monday, May 13, 2024.
I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead.
Thomas Hong
Good afternoon and thank you for joining the INOVIO first quarter 2024 financial results conference call. Joining me on today's call are Dr. Jacque Shea, President and CEO; Dr. Michael Sumner, Chief Medical Officer; Mark Twyman, Chief Commercial Officer; and Peter Kies, Chief Financial Officer.
Today's call will review our corporate and financial information for the quarter ended March 31, 2024, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment.
During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop INOVIO's DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today.
Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading “Risk Factors” identify important factors that could cause actual results to differ materially from those expressed by the company verbally as well as statements made within this afternoon's press release....
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript